219 related articles for article (PubMed ID: 9696656)
1. Effect of troglitazone in type 2 diabetes mellitus.
Rusk MH
N Engl J Med; 1998 Aug; 339(6):406. PubMed ID: 9696656
[No Abstract] [Full Text] [Related]
2. Effect of troglitazone in type 2 diabetes mellitus.
Gorson DM
N Engl J Med; 1998 Aug; 339(6):406. PubMed ID: 9696655
[No Abstract] [Full Text] [Related]
3. Deterioration of glycemic control after long-term treatment with troglitazone in nonobese type 2 diabetic patients.
Murase Y; Wakasugi T; Yagi K; Mabuchi H
Diabetes Care; 2000 Jan; 23(1):131-2. PubMed ID: 10857989
[No Abstract] [Full Text] [Related]
4. Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-diabetics.
Iwatani M; Wasada T; Katsumori K; Watanabe-Takahashi C; Kamatani N; Iwamoto Y
Diabetologia; 2000 Jun; 43(6):814-5. PubMed ID: 10907128
[No Abstract] [Full Text] [Related]
5. Effects of troglitazone in patients with type 2 diabetes mellitus not adequately controlled by sulfonylureas.
Bunnag P; Puavilai G; Chanprasertyotin S; Chandraprasert S; Suwanwalaikorn S; Suthijumroon A; Benjasuratwong Y; Boonyavarakul A; Nitiyanant W; Sriussadaporn S; Deerochanawong C;
Diabetes Res Clin Pract; 2001 Feb; 51(2):151-3. PubMed ID: 11253769
[No Abstract] [Full Text] [Related]
6. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones.
King AB
Diabetes Care; 2000 Apr; 23(4):557. PubMed ID: 10857952
[No Abstract] [Full Text] [Related]
7. A treatment for Mr WP: thiazolidinediones after troglitazone.
Montague CT
Diabet Med; 2002; 19 Suppl 1():7-9. PubMed ID: 11871423
[No Abstract] [Full Text] [Related]
8. Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success.
Nagasaka S; Abe T; Kawakami A; Kusaka I; Nakamura T; Ishikawa S; Saito T; Ishibashi S
Diabet Med; 2002 Apr; 19(4):347-8. PubMed ID: 11943013
[No Abstract] [Full Text] [Related]
9. Using dose-response characteristics of therapeutics agents for treatment decisions in type 2 diabetes.
Garber AJ
Diabetes Obes Metab; 2000 Jun; 2(3):139-47. PubMed ID: 11220549
[No Abstract] [Full Text] [Related]
10. [Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].
Ohmura E; Hosaka D; Imai Y; Kawazu S
Nihon Rinsho; 2002 Sep; 60 Suppl 9():470-5. PubMed ID: 12387036
[No Abstract] [Full Text] [Related]
11. Switching insulin-sensitizing agents in patients with type 2 diabetes who require insulin.
Blonde L; Sandberg MI; Guthrie RD
Diabetes Care; 1999 Jun; 22(6):1004-6. PubMed ID: 10372262
[No Abstract] [Full Text] [Related]
12. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.
Schwartz S; Raskin P; Fonseca V; Graveline JF
N Engl J Med; 1998 Mar; 338(13):861-6. PubMed ID: 9516220
[TBL] [Abstract][Full Text] [Related]
13. Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes.
Katsuki A; Sumida Y; Murata K; Furuta M; Araki-Sasaki R; Tsuchihashi K; Hori Y; Yano Y; Gabazza EC; Adachi Y
Diabetes Obes Metab; 2000 Jun; 2(3):189-91. PubMed ID: 11220554
[TBL] [Abstract][Full Text] [Related]
14. Troglitazone directly increases HDL cholesterol levels.
Nozue T; Michishita I; Minagawa F; Genda A
Diabetes Care; 1999 Feb; 22(2):355-6. PubMed ID: 10333957
[No Abstract] [Full Text] [Related]
15. Serum leptin level as an indicator to predict the clinical efficacy of troglitazone in patients with type 2 diabetes mellitus.
Maruyama S; Yanagisawa K; Kanamuro R; Teno S; Iwamoto Y
Diabetes Res Clin Pract; 2001 Sep; 53(3):161-4. PubMed ID: 11483231
[TBL] [Abstract][Full Text] [Related]
16. Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus.
Kato K; Yamada D; Midorikawa S; Sato W; Watanabe T
Metabolism; 2000 May; 49(5):662-5. PubMed ID: 10831180
[TBL] [Abstract][Full Text] [Related]
17. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
[TBL] [Abstract][Full Text] [Related]
18. The rise and fall of troglitazone.
Bailey CJ
Diabet Med; 2000 Jun; 17(6):414-5. PubMed ID: 10975209
[No Abstract] [Full Text] [Related]
19. Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.
Raskin P; Jovanovic L; Berger S; Schwartz S; Woo V; Ratner R
Diabetes Care; 2000 Jul; 23(7):979-83. PubMed ID: 10895850
[TBL] [Abstract][Full Text] [Related]
20. Effect of troglitazone on lipoprotein(a) levels in obese subjects.
Tack CJ; Smits P; DeMacker PN; Stalenhoef AF
Diabetes Care; 1999 Oct; 22(10):1752-3. PubMed ID: 10526754
[No Abstract] [Full Text] [Related]
[Next] [New Search]
